FDA Mutual Reliance with EU on Inspections Is Slow Going
This article was originally published in The Gold Sheet
Executive Summary
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
You may also be interested in...
Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US
Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.
Despite Globalization, Three Quarters of Serious Issues FDA Found Were in US
FDA inspection results data show that even as the agency responded to the threat of poor drug quality abroad in fiscal years 2009-2014, it was more successful at finding serious quality issues during its much more numerous domestic inspections. Asian inspections were somewhat more likely to identify serious issues than US ones, while European inspections were much less likely to raise any, and neither identified nearly as many.
FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says
In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.